We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Revises Guidance for Sponsors of Rare Disease Drug Trials
FDA Revises Guidance for Sponsors of Rare Disease Drug Trials
As the partial government shutdown grinds on, the FDA resumed issuing guidance on Wednesday with a revised draft guidance to help sponsors of rare disease treatments conduct more effective clinical trials.